Korro Bio, Inc.

For the period ended Jun 30, 2025. Filed Aug 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 12, 2025

KRRO$15.73+5.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(amounts in thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenue:
Collaboration revenue	$1,460	$—	$4,010	$—
Operating expenses:
Research and development	21,031	17,138	40,770	30,710
General and administrative	7,631	6,987	15,462	14,868
Total operating expenses	28,662	24,125	56,232	45,578
Loss from operations	(27,202)	(24,125)	(52,222)	(45,578)
Other income:
Other income, net	1,433	2,329	3,066	4,242
Total other income, net	1,433	2,329	3,066	4,242
Loss before provision for income taxes	(25,769)	(21,796)	(49,156)	(41,336)
Provision for income taxes	(1)	(30)	(1)	(47)
Net loss	$(25,770)	$(21,826)	$(49,157)	$(41,383)
Other comprehensive income:
Unrealized (loss) gain on available-for-sale marketable securities	(74)	21	(77)	21
Foreign currency translation adjustments, net	(13)	—	(14)	—
Comprehensive loss	$(25,857)	$(21,805)	$(49,248)	$(41,362)
Net loss per share, basic and diluted	$(2.74)	$(2.43)	$(5.24)	$(4.87)
Weighted-average shares used in computing net loss per share, basic and diluted	9,390,542	8,986,545	9,386,597	8,503,086

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.